Sensei Biotherapeutics stock increased 230% on Wednesday, reaching a 52-week high of $30.12, following the company's acquisition of Faeth Therapeutics and a concurrent $200 million private investment round. The transaction substantially expands Sensei's clinical pipeline with the addition of PIKTOR, an investigational oral combination therapy targeting the PI3K/AKT/mTOR pathway, addressing a key signaling cascade implicated in multiple cancer types.
Under the terms of the deal, Sensei has gained access to PIKTOR's clinical development program, which targets significant oncology indications with substantial unmet medical needs. The company intends to advance the asset through Phase 2 clinical trials in patients with advanced endometrial cancer and Phase 1b trials in patients with hormone receptor-positive, HER2-negative advanced breast cancer, with both programs expected to reach key milestones by the end of 2026.
The acquisition and concurrent financing demonstrate investor confidence in Sensei's strategy to expand its pipeline in immuno-oncology and targeted therapeutics. The influx of capital provides the company with resources to support the accelerated development timeline for PIKTOR and other programs within its portfolio.